THALES
7.9.2020 08:02:09 CEST | Business Wire | Press release
OPPO, the world's leading smart device manufacturer, has selected Thales’ set of eSIM products and services for its OPPO Watch, the brand’s first smartwatch series with built-in cellular connectivity. The launch of the OPPO Watch marks a strategic step into the field of IoT for the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200906005025/en/
One of the most compelling features of the OPPO Watch is the eSIM-based cellular connectivity. Thales’ eSIM allows OPPO Watch users to enjoy a smoothly digital experience by activating a mobile subscription remotely and always stay connected without having to tether it to a mobile phone. Users can make voice calls or send messages at any time directly through the smartwatch, providing seamless connectivity during workouts or other situations where carrying a mobile phone is inconvenient. This smooth experience leverages Thales eSIM solutions to offer a full range of subscription services during the life cycle of the device.
By eliminating the need for an additional SIM card slot, Thales’ eSIM makes sleek mobile-connected smartwatches possible. Indeed it enables a thinner and lighter smartwatch design while freeing up more space for extra features such as up to 50 meter water resistance. It thereby helps OPPO fulfil its mission of elevating life through technological artistry.
The Thales embedded SIM has been qualified by all three China’s mobile operators allowing OPPO smartwatch users to select their mobile subscription from any of these operators.
“As OPPO's first foray into the wearable electronics
market, the OPPO Watch marks a strategic step into the field of AIoT (Artificial IoT) for the company. Thanks to Thales' eSIM solutions that bring smartphone-level convenience to smartwatches, users can stay connected in a smarter and more efficient way without restrictions. We are looking forward to working with Thales again, given their leadership in eSIM and the success of our current partnership.”
Liu Bo, President of OPPO China
“The wearable segment is the second largest market for eSIM-compliant consumer electronics after smartphones. ABI Research forecasts that a total of 315 million cellular enabled wearables will have shipped by 2025. Smartwatch makers, in particular, are increasingly on-boarding eSIM connectivity in their flat-design devices to address new smartwatch-only use cases such as kids safety, sports and health monitoring...”
David McQueen, Director, Connected Consumer Devices, ABI Research
Research
“Thales is honoured to provide a full suite of eSIM solutions for OPPO Watch. AIoT is one of OPPO’s key focuses aiming to bring customers seamless experiences to their daily life, including sport and health. Thales is OPPO’s key eSIM solutions partner, empowering them with instant connectivity for their consumer devices. We are proud to accompany OPPO on this journey and fully support their ambitions of providing their users with the best innovations available.”
Jérôme Bendell, Vice President of Thales North Asia and CEO of Thales in China
Thales is the world's leader in eSIM connectivity management with more than 200 eSIM management platforms awarded by mobile operators, operator alliances, MVNOs, automotive makers, and OEMs across all continents.
Related resources:
What is an eSIM: 6 illustrated answers
infographic
4 ways to activate eSIM-capable consumer IoT devices
dossier
Best practices for optimising eSIM adoption
eBook
Innovative eSIM use cases such as prepaid offers for inbound travelers and family bundle
dossier
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations – connectivity, Big Data, artificial intelligence and cybersecurity – technologies that support businesses, organisations and governments in their decisive moments.
About Thales in China
Thales provides innovative solutions for the infrastructure that forms the backbone of China’s growth. The Group has been present in China for around 40 years and is the trusted partner for the Chinese aviation and urban rail transportation industries. In the meanwhile, from secure software to biometrics and encryption, Thales has successfully applied its advanced technology to mobile communication, banking, IoT and software monetization etc. Thales has 3 JVs and employs 2,300 people with offices located in 8 cities in China. Thales established R&D centers and Innovation Hubs in Beijing, Dalian and Hong Kong to provide innovative solutions for both China and international market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200906005025/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom